Progyny (NASDAQ:PGNY) Issues Q3 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.500-0.520 for the period, compared to the consensus EPS estimate of 0.470. The company issued revenue guidance of $335.0 million-$345.0 million, compared to the consensus revenue estimate of $350.2 million. Progyny also updated its FY 2026 guidance to 2.040-2.100 EPS.

Progyny Stock Performance

PGNY opened at $28.10 on Friday. The company has a market cap of $2.20 billion, a PE ratio of 30.54, a price-to-earnings-growth ratio of 2.40 and a beta of 1.01. The stock has a 50-day moving average of $29.08 and a 200-day moving average of $23.43. Progyny has a 52-week low of $16.10 and a 52-week high of $33.06.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a net margin of 6.00% and a return on equity of 15.57%. The company’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.17 earnings per share. On average, research analysts predict that Progyny will post 1.19 earnings per share for the current year.

Progyny declared that its board has authorized a share buyback program on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to buy up to 10.3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PGNY. BTIG Research lifted their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Weiss Ratings raised Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Citizens Jmp upped their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. Finally, Truist Financial increased their price objective on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.20.

Insider Activity

In other news, Director Cheryl Scott sold 7,439 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the transaction, the director directly owned 19,772 shares of the company’s stock, valued at approximately $521,783.08. This trade represents a 27.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark S. Livingston sold 2,517 shares of Progyny stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer owned 74,688 shares in the company, valued at approximately $1,904,544. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 36,916 shares of company stock valued at $939,875. 9.90% of the stock is owned by insiders.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter earnings of $0.55 per share, well above the $0.33 consensus estimate, while revenue of $350.5 million modestly exceeded expectations of $348.6 million. Revenue increased 5.3% year over year, and earnings improved from $0.19 per share in the prior-year quarter. Progyny Announces Second Quarter 2026 Results
• Positive Sentiment: Full-year 2026 adjusted EPS guidance of $2.04 to $2.10 is above the analyst consensus of $1.86, signaling confidence in profitability. Full-year revenue guidance of approximately $1.4 billion is broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: CEO Pete Anevski is scheduled to present at the Canaccord Genuity Annual Growth Conference on August 11. The event could provide additional detail on client demand, growth initiatives and the company’s outlook, but it does not immediately change financial results. Progyny to Present at Canaccord Genuity Conference
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million is below the $350.2 million analyst consensus. Although projected EPS of $0.50 to $0.52 exceeds the $0.47 consensus, investors appear more concerned about slower top-line momentum and the possibility that growth remains muted. Why Progyny Shares Are Sliding Today

Hedge Funds Weigh In On Progyny

Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its holdings in Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after buying an additional 457 shares during the last quarter. Teza Capital Management LLC lifted its stake in Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after acquiring an additional 516 shares during the last quarter. Aristides Capital LLC grew its position in shares of Progyny by 4.6% in the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after acquiring an additional 528 shares during the period. Oxford Asset Management LLP increased its stake in shares of Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after purchasing an additional 531 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Progyny by 0.8% during the 3rd quarter. Alliancebernstein L.P. now owns 96,620 shares of the company’s stock worth $2,079,000 after purchasing an additional 723 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.